European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Today

In the landscape of pharmaceutical quality control, few documents carry as much authoritative weight as the monographs of the . For manufacturers seeking to market oral solid dosage forms within the 38 member states of the European Pharmacopoeia Convention (and beyond, via the CE marking or WHO prequalification), compliance is non-negotiable.

According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are typically produced by compressing uniform volumes of particles but can also be made through extrusion, moulding, or freeze-drying (lyophilisation).

This monograph does not apply to lozenges, oral pastes, or oral gums, which are covered under other sections like Oromucosal Preparations (1807) . Primary Tablet Categories European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Dissolution testing evaluates the rate at which the API is released from the tablet matrix into a liquid medium, simulating human physiological conditions. This is a critical surrogate marker for in vivo drug absorption and bioavailability. Modified-release and gastro-resistant tablets require highly specialized dissolution profiles (e.g., testing in acid medium followed by a buffer change). C. Disintegration (2.9.1)

: Evaluates the hard break threshold by applying direct compression force across the diameter of 10 sample tablets. Results are quantified and logged meticulously in Newtons. In the landscape of pharmaceutical quality control, few

Tablets are defined as solid dosage forms that are prepared by compressing a mixture of active pharmaceutical ingredients and excipients. The tablets must be uniform in size, shape, and weight, and must meet specific requirements for hardness, friability, and disintegration.

Her team met weekly with formulation scientists and quality-control analysts. Today’s agenda: a proposed update to the disintegration test in 0478. The change was technical but consequential — a small reduction in permitted disintegration time for chewable tablets intended for pediatric use. The lab’s dissolution profiles showed many current formulations would pass, but a few marginal products might fail. The meeting began with silence, then a measured exchange of data and risk assessments. They are typically produced by compressing uniform volumes

Monograph 0478 defines tablets as solid preparations containing a single dose of one or more active substances. They are primarily produced by compressing particles but can also be made through extrusion or freeze-drying (oral lyophilisates). This general monograph covers various categories, including: . Gastro-resistant and Modified-release Tablets . Effervescent, Soluble, and Dispersible Tablets .

If you need a deep dive into the for tests like the Uniformity of Dosage Units (2.9.40)?

| Feature | Ph. Eur. 0478 | USP <701> / <711> | JP (Tablets) | |---------|---------------|--------------------|---------------| | Scope | Uncoated & film-coated only | Includes chewable, buccal, etc. | Broader – includes effervescent | | Dissolution | 2.9.3 with Q-value | <711> with S1, S2, S3 stages | Similar to USP | | Disintegration | Permitted as alternative | Not a substitute for dissolution (except BCS Class I or III) | Permitted | | Friability | Optional unless specified | Mandatory (USP <1216>) | Mandatory | | Hardness | Not required | Not required but common | Not required |